Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cenovus Energy Inc (CVE) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance

Cenovus Energy IncTrade
IDEXX Laboratories, Inc.Trade

Price performance (Past 24H)

Key statistics

Cenovus Energy Inc vs IDEXX Laboratories, Inc. — how do they compare? Cenovus Energy Inc trades at $30.2 (market cap $55.00B), while IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B). The key difference: Cenovus Energy Inc is the larger of the two by market cap, and Cenovus Energy Inc pays a 2.09% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.

CVEIDXX
Market Cap
$55.00B$46.22B
Sector
EnergyHealth
52-Week High
$31.80$766.68
52-Week Low
$14.83$526.44
Enterprise Value
$61.08B$47.12B
Dividend Yield
2.09%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cenovus Energy Inc

Cenovus Energy (CVE) trades at $30.14, up 1.96% with bullish technical signals and strong fundamentals. The stock shows robust earnings momentum with recent quarterly beats, supported by record oil sands production and disciplined cost management. Valuation metrics remain attractive with P/E of 11.56 and EV/EBITDA of 5.77, while profitability metrics include 11.48% net income margin and 20.96% ROE. Recent news highlights institutional buying interest and strong Q2 2026 operational performance.

CVE presents a compelling investment case with undervalued metrics and positive earnings trajectory, though exposure to volatile oil prices and refining margins poses risks. Analyst consensus leans bullish with 40.7% buy ratings, while technical indicators suggest continued upward momentum. The company's integrated model and growth projects support long-term value creation for shareholders.

IDEXX Laboratories, Inc.

IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.

The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cenovus Energy Inc

Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.

Read more on CVE

About IDEXX Laboratories, Inc.

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

Read more on IDXX